GCG and fatty liver disease: When administered a glucagon/GLP-1 receptor co-agonist, type 2 diabetic and obese rodents displayed reduced hepatic steatosis, increased hormone-sensitive lipase (HSL) activity in adipocytes, and improved dyslipidemia [187,188,189,190,191,192,193].